Skip to Content

ASCEND Therapeutics, Inc. to Present Phase 2 Data from Breast Tumor Cell Proliferation Study; Data Will Be Presented at the 26th Annual San Antonio Breast Cancer Symposium

HERNDON, Va., Nov. 24, 2003--ASCEND Therapeutics, Inc. announced today that it will present data from a Phase 2 dose-escalating study comparing the Company's percutaneous TamoGel(TM) (4-Hydroxytamoxifen gel) to orally administered tamoxifen.

The data will be presented at the 26th Annual San Antonio Breast Cancer Symposium being held December 3 - 6, 2003 in San Antonio, Texas.

Date: Saturday, December 6, 2003

Time: 7:00 - 9:00 am (CST)

Presenters: Dana Hilt, MD, Chief Medical Officer, ASCEND


Philippe Rouanet, MD, Centre Val d'Aurelle, Montpellier, France

Poster: Poster # 687

Session Title: Treatment: Neoadjuvent Chemotherapy

About TamoGel(TM)

TamoGel(TM) is a percutaneously applied gel formulation of 4- Hydroxytamoxifen (4-OHT) that is currently under investigation in a variety of benign and malignant estrogen-dependent conditions by ASCEND Therapeutics. 4-OHT is a metabolite of tamoxifen that is up to 100 times more potent than tamoxifen in inhibiting breast cell proliferation in vitro. (Malet, Cancer Research, 1988). TamoGel(TM) is formulated as an enhanced hydroalcoholic gel for transdermal delivery. I.e., the gel is applied directly to the surface of the breast, where it is absorbed into the breast tissue.

About ASCEND Therapeutics

Based in Herndon, Virginia, ASCEND Therapeutics, Inc. is a biopharmaceutical company engaged in the discovery and development of innovative therapeutic products for the treatment of underserved chronic conditions. ASCEND's initial product pipeline includes transdermal hydroalcoholic gel-based products in the areas of women's and men's health. ASCEND's gel product TamoGel(TM) is currently in two separate Phase 2 clinical trials for breast pain and breast density. DHT, its product for elderly hypogonadism, will begin Phase 2 trials in 2004.

For more information, visit ASCEND's web site at

    CONTACT: LaVoie Strategic Communications Group, Inc.

             Barbara Askjaer, 781/599-4774 X102


Posted: November 2003